(Abstracted from Am J Obstet Gynecol 2017;217(3):282–302)
Metformin (dimethylbiguanide hydrochloride) was initially introduced as an antidiabetic agent; however, in recent years, it has shown a wide array of beneficial effects ranging from cancer therapy to extending longevity. As a gestational antidiabetic agent, metformin has compared favorably to insulin by showing a significantly reduced frequency of neonatal hyperglycemia, large-for-gestational-age neonates, and admissions to a neonatal intensive care unit compared with those treated with insulin.
The Perinatology Research Branch, Program for Perinatal Research and Obstetrics, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, US Department of Health and Human Services (NICHD/NIH/DHHS), Bethesda, MD; and Detroit (R.R., O.E., E.M., B.P., A.C.-A., P.P.); Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor (R.R.); Department of Epidemiology and Biostatistics, Michigan State University, East Lansing (R.R.); Center for Molecular Medicine and Genetics, Wayne State University (R.R., M.H., L.I.G.); Department of Obstetrics and Gynecology, Wayne State University School of Medicine (O.E., E.M., B.P., P.P.), Detroit, MI; Department of Obstetrics and Gynecology, Soroka University Medical Center School of Medicine, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beersheba, Israel (O.E., E.M.); and Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Republic of Korea (B.H.Y.)